Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
Mar 11, 2022
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
Mar 10, 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
Mar 01, 2022
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
Feb 10, 2022
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
Feb 04, 2022
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference
Jan 26, 2022
Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million
Jan 24, 2022
Tiziana Life Sciences Announces Death of Director
Jan 13, 2022
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis
Jan 10, 2022
Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference
Jan 06, 2022
Displaying 41 - 50 of 423